Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway.
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Hofseth BioCare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HBQ's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HBQ exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: HBQ exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Hofseth BioCare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hofseth BioCare undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HBQ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HBQ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HBQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: HBQ is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HBQ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HBQ is overvalued based on its PB Ratio (20.1x) compared to the DE Biotechs industry average (3.5x).
How is Hofseth BioCare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hofseth BioCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Hofseth BioCare's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Hofseth BioCare competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Hofseth BioCare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HBQ is currently unprofitable.
Growing Profit Margin: HBQ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HBQ is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare HBQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: HBQ has a negative Return on Equity (-64.41%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Hofseth BioCare's financial position?
Financial Position Analysis
Short Term Liabilities: HBQ's short term assets (NOK148.3M) exceed its short term liabilities (NOK69.4M).
Long Term Liabilities: HBQ's short term assets (NOK148.3M) exceed its long term liabilities (NOK107.0M).
Debt to Equity History and Analysis
Debt Level: HBQ's debt to equity ratio (91.2%) is considered high.
Reducing Debt: HBQ's debt to equity ratio has reduced from 117.3% to 91.2% over the past 5 years.
Inventory Level: HBQ has a high level of physical assets or inventory.
Debt Coverage by Assets: HBQ's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HBQ has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HBQ has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 12% each year.
What is Hofseth BioCare's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HBQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBQ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBQ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HBQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Hofseth (45yo)
Mr. Roger Hofseth has been the Chief Executive Officer of Hofseth BioCare ASA since August 14, 2017. He is Director at Aqua Bio Technology ASA since January 9, 2019. Mr. Hofseth serves as the Chief Executi ...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD625.18K).
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||3.5yrs||kr1.63m||0.70% NOK1.8m|
|Chief Scientific Officer||10.1yrs||kr4.33m||0.27% NOK686.9k|
|Lab Manager & Director||6.2yrs||kr902.00k||no data|
|Chief Executive Officer||2.5yrs||kr483.71k||14.71% NOK37.1m|
|Chief Operating Officer||2.8yrs||no data||no data|
|Marketing Manager||5.5yrs||kr902.00k||no data|
|Managing Partner of Hofseth North America||4.1yrs||kr1.09m||no data|
|Executive||0yrs||no data||no data|
Experienced Management: HBQ's management team is considered experienced (4.1 years average tenure).
|Lab Manager & Director||6.2yrs||kr902.00k||no data|
|Independent Director||5.1yrs||kr96.00k||0.18% NOK449.3k|
|Independent Director||4.7yrs||kr116.00k||no data|
Experienced Board: HBQ's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.
Hofseth BioCare ASA's company bio, employee growth, exchange listings and data sources
- Name: Hofseth BioCare ASA
- Ticker: HBQ
- Exchange: DB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr2.541b
- Listing Market Cap: kr252.409m
- Shares outstanding: 325.82m
- Website: https://www.hofsethbiocare.no
Number of Employees
- Hofseth BioCare ASA
- Havnegata 11
- Møre og Romsdal
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HBC||OB (Oslo Bors)||Yes||Common Shares||NO||NOK||Dec 2011|
|0Q6H||LSE (London Stock Exchange)||Yes||Common Shares||GB||NOK||Dec 2011|
|HBCO||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||NOK||Dec 2011|
|HOFB.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Dec 2011|
|HBQ||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Dec 2011|
Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company was founded in 2000 and is headquartered in Ålesund, Norway.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 23:58|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.